- Home
- DSU vs MREO Comparison
DSU vs MREO Comparison
Compare DSU & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSU
- MREO
- Stock Information
- Founded
- DSU 1998
- MREO 2015
- Country
- DSU United States
- MREO United Kingdom
- Employees
- DSU N/A
- MREO N/A
- Industry
- DSU Finance Companies
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- DSU Finance
- MREO Health Care
- Exchange
- DSU Nasdaq
- MREO Nasdaq
- Market Cap
- DSU 548.1M
- MREO 438.8M
- IPO Year
- DSU N/A
- MREO N/A
- Fundamental
- Price
- DSU $10.52
- MREO $1.74
- Analyst Decision
- DSU
- MREO Strong Buy
- Analyst Count
- DSU 0
- MREO 5
- Target Price
- DSU N/A
- MREO $7.20
- AVG Volume (30 Days)
- DSU 148.2K
- MREO 1.8M
- Earning Date
- DSU 01-01-0001
- MREO 08-12-2025
- Dividend Yield
- DSU 10.06%
- MREO N/A
- EPS Growth
- DSU N/A
- MREO N/A
- EPS
- DSU N/A
- MREO N/A
- Revenue
- DSU N/A
- MREO $500,000.00
- Revenue This Year
- DSU N/A
- MREO N/A
- Revenue Next Year
- DSU N/A
- MREO $38.38
- P/E Ratio
- DSU N/A
- MREO N/A
- Revenue Growth
- DSU N/A
- MREO N/A
- 52 Week Low
- DSU $9.22
- MREO $1.47
- 52 Week High
- DSU $11.40
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- DSU 45.35
- MREO 44.98
- Support Level
- DSU $10.51
- MREO $1.64
- Resistance Level
- DSU $10.59
- MREO $1.78
- Average True Range (ATR)
- DSU 0.05
- MREO 0.09
- MACD
- DSU -0.01
- MREO 0.04
- Stochastic Oscillator
- DSU 16.67
- MREO 87.10
About DSU Blackrock Debt Strategies Fund Inc.
Blackrock Debt Strategies Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide current income by investing in a diversified portfolio of U.S. companies' debt instruments including corporate loans. The fund's secondary investment objective is to provide capital appreciation.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).